MarketLens

Pricing Plans Sign Up Log in

Pro Investment Ideas

The $100 Billion Weight Loss Revolution That's Reshaping Your Portfolio

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

3 weeks ago

SanDisk Just Joined the S&P 500—Here's What That Actually Means for Your Portfolio

4 months ago

From Value Meals to Weight-Loss Drugs: Navigating the Evolving Consumer Landscape

2 months ago

Is the AI Revolution Reshaping Mid-Cap Tech

1 months ago

Boehringer Ingelheim's Obesity Drug Helps Lose Fat Rather Than Muscle, Late-Stage Trial Shows

Boehringer Ingelheim’s obesity drug, survodutide, demonstrated a targeted reduction in visceral fat while preserving muscle mass in late-stage clinical trials. This efficacy profile could differentiat...

Stock News•2 days ago

Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

Revolution Medicines maintains a $29B market capitalization despite generating no revenue, driven by investor optimism surrounding its pancreatic cancer candidate, daraxonrasib. The drug significantly...

RVMD

Stock News•4 days ago

Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?

Eli Lilly is expanding its footprint within the weight-loss drug market to drive future growth. The company remains a dominant player in the sector as it scales production and pursues further market p...

LLY

Stock News•4 days ago

Menu-Order-AI Surpasses 110,000 Downloads as It Targets the Biggest Gap in the GLP-1 Era: What to Order

Menu-Order-AI surpassed 110,000 downloads within 4.5 months of its launch. The app targets the dining needs of GLP-1 users, suggesting strong consumer interest in specialized nutritional guidance duri...